|

AI-Personalized Discharge Education for Patients After Lung Cancer Surgery

RECRUITINGN/ASponsored by Xiamen University
Actively Recruiting
PhaseN/A
SponsorXiamen University
Started2026-08-15
Est. completion2026-10-15
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted

Summary

This randomized controlled trial evaluates the effect of artificial intelligence (AI)-personalized discharge education on discharge teaching quality and recovery outcomes in patients after lung cancer surgery. Eligible participants will be randomly assigned in a 1:1 ratio to either an intervention group or a control group. The control group will receive routine discharge education, including verbal instructions and a standardized printed discharge booklet. The intervention group will receive the same routine education plus an AI-generated personalized discharge guidance plan based on individual clinical and care-related information. All AI-generated content will be reviewed by a responsible nurse before being provided to participants. The primary outcome is the quality of discharge teaching measured on the day of discharge. Secondary outcomes include self-efficacy for postoperative rehabilitation management and quality of life assessed one month after discharge.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Pathologically confirmed primary lung cancer and underwent radical lung cancer surgery by thoracoscopic or open approach, including lobectomy, pneumonectomy, or wedge resection.
2. Age 18 to 80 years.
3. Clinical stage I to III.
4. No distant organ metastasis.
5. Clinically stable after surgery, conscious, and able to perform basic listening, speaking, and reading activities, with planned discharge to home for recovery.
6. The participant or primary caregiver is able to use a smartphone and WeChat.
7. Able and willing to provide informed consent and voluntarily participate in the study.

Exclusion Criteria:

1. Recurrent lung cancer or previous treatment with targeted therapy, chemotherapy, or radiotherapy.
2. Severe aphasia, cognitive impairment (MMSE \<24), or psychiatric disorders that prevent independent completion of study questionnaires.
3. Severe cardiac, hepatic, or renal dysfunction, or another malignant tumor.
4. Severe postoperative complications requiring prolonged hospitalization, such as bronchopleural fistula or major bleeding.
5. Participation in another interventional clinical study.
6. Unable to complete the 1-month follow-up because of travel or residence outside the study area after discharge.

Conditions3

CancerLung CancerLung Cancer (Diagnosis)

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.